



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 2, 2025

Christopher Schaber
Chief Executive Officer
Soligenix, Inc.
29 Emmons Drive, Suite B-10
Princeton, NJ 08540

Re: Soligenix, Inc.
Draft Registration Statement on Form S-1
Submitted August 27, 2025
CIK No. 0000812796

Dear Christopher Schaber:

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Driscoll R. Ugarte, Esq.